ABLYNX SUCCESSFULLY OPPOSES PATENT APPEAL CASE BY DOMANTIS (GSK)

(Thomson Reuters ONE) -


GHENT, Belgium, 22 January 2015 - Ablynx [Euronext Brussels: ABLX] today
announced that it has been successful in opposing the appeal lodged by Domantis
(now a member of the GlaxoSmithKline, GSK, group of companies) in 2010 against
the decision by the Opposition Division of the European Patent Office to revoke
Domantis' European Patent 1 517 921. As a result of the decision by the Board of
Appeal, the Domantis patent will remain revoked in full (without further
possibility to appeal).


The European Patent 1 517 921 relates to one specific technique for the half-
life extension of immunoglobulin single variable domains. Now that the
revocation of this patent has been confirmed in appeal, Ablynx and its partners
remain free to apply such half-life extension techniques in their internal and
partnered programmes, as Domantis has no granted patent claims that could
possibly be invoked against the use of these techniques in Europe.

Dr Edwin Moses, CEO of Ablynx, commented:

"This is the result that we have always anticipated. One of the key features of
our Nanobody® technology is the possibility for modular half-life extension to
achieve the desired properties, such as the use in chronic versus acute
indications. Today, we have already achieved two clinical proof-of-concepts in
patients with rheumatoid arthritis with two Nanobodies that incorporate this
half-life extension technology. From all the evidence available to us, our half-
life extension technology, which is based on a serum-albumin binding Nanobody,
outperforms that of GSK/Domantis. We are pleased that the Board of Appeal has
now rejected attempts by Domantis to claim our proprietary techniques in their
patents."

Ablynx was represented by Dr Joe Taormino and Dr Andreas Stefferl from the firm
of Hoffmann-Eitle in Munich.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
30 proprietary and partnered programmes in development in therapeutic areas
including inflammation, haematology, oncology and respiratory disease. The
Company has collaborations and significant partnerships with pharmaceutical
companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and
Novartis. The Company is headquartered in Ghent, Belgium. More information can
be found on www.ablynx.com.


For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses(at)ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX

Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t:   +44 203 709 5700
e:  ablynx(at)consilium-comms.com



pdf format of the press release:
http://hugin.info/137912/R/1888654/668376.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via GlobeNewswire
[HUG#1888654]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 22.01.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 366134
Anzahl Zeichen: 4284

contact information:
Town:

Ghent/Zwijnaarde

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 229 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX SUCCESSFULLY OPPOSES PATENT APPEAL CASE BY DOMANTIS (GSK)"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx